Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.7 EUR | -36.94% |
|
0.00% | 0.00% |
Sales 2024 | 4,264B 26.92B 25.11B | Sales 2025 * | 4,281B 27.03B 25.21B | Capitalization | 6,312B 39.85B 37.16B |
---|---|---|---|---|---|
Net income 2024 | 144B 910M 848M | Net income 2025 * | 92.57B 585M 545M | EV / Sales 2024 | 2.57 x |
Net Debt 2024 | 4,386B 27.69B 25.82B | Net Debt 2025 * | 4,189B 26.45B 24.66B | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
69.4
x | Employees | 49,095 |
Yield 2024 |
4.49% | Yield 2025 * |
4.84% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | -36.94% |
![Extreme 2.5398](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.93% | 803B | |
+40.71% | 631B | |
-7.08% | 351B | |
+17.40% | 324B | |
+10.58% | 303B | |
+16.34% | 243B | |
+2.09% | 228B | |
+10.27% | 217B | |
+6.24% | 164B |
- Stock Market
- Equities
- 4502 Stock
- 0RN3 Stock